The potential role of belantamab mafodotin in multiple myeloma

DREAMM-9: The potential role of belantamab mafodotin in the frontline treatment of multiple myelomaПодробнее

Belantamab mafodotin: a potential new SoC in second-line myeloma based on the DREAMM trialsПодробнее

The promise of belantamab mafodotin for the treatment of multiple myelomaПодробнее

Mechanism of action of belantamab mafodotinПодробнее

Dr Krishnan on the Evolving Role of Belantamab Mafodotin in Multiple MyelomaПодробнее

An update on the use of belantamab mafodotin in multiple myelomaПодробнее

Dr. Raje on the Potential Utility of Belantamab Mafodotin in Multiple MyelomaПодробнее

What is the current status of belantamab and its potential reapproval?Подробнее

DREAMM-5 Study of BLENREP (belantamab mafodotin) Combined with Nirogacestat in RRMM patientsПодробнее

The role of belantamab mafodotin in myeloma treatment and managing the associated ocular toxicitiesПодробнее

Belantamab mafodotin: ocular toxicityПодробнее

Role of BCMA-targeting ADCs in the management of myelomaПодробнее

What is GSK 2857916, also known as belantamab mafodotin?Подробнее

BLENREP (belantamab mafodotin-blmf) Mechanism of Action in Multiple MyelomaПодробнее

Belantamab mafodotin in myeloma: advantages and disadvantagesПодробнее

DREAMM-5 platform trial: Belantamab mafodotin in combination with novel agents in patients with RRMMПодробнее

Belantamab mafodotin in R/R myeloma and methods of reducing ocular toxicityПодробнее

Dr. Lonial on Data With Belantamab Mafodotin in Multiple MyelomaПодробнее

DREAMM-2: Single-Agent Belantamab Mafodotin in Patients with RRMM and Renal ImpairmentПодробнее